# Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study.

> PubMed lists PMID 19546056 in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009 Nov-Dec (source-text precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19546056-pramlintide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19546056-pramlintide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-19546056-pramlintide-v1.json
- Content SHA-256: `877e40b72bd004378e6728031db5d991f5f5507dd44ca07b6508fce005844230`

## Claims and source pins

### Headline

Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study. ([`pubmed-observation-pmid-19546056-2026-01-28-f23ada615c88`](#source-pubmed-observation-pmid-19546056-2026-01-28-f23ada615c88))

### Summary

PubMed lists PMID 19546056 in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009 Nov-Dec (source-text precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19546056-2026-01-28-f23ada615c88`](#source-pubmed-observation-pmid-19546056-2026-01-28-f23ada615c88))

### Paragraph 1

PubMed lists PMID 19546056 in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009 Nov-Dec (source-text precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19546056-2026-01-28-f23ada615c88`](#source-pubmed-observation-pmid-19546056-2026-01-28-f23ada615c88))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19546056-2026-01-28-f23ada615c88`](#source-pubmed-observation-pmid-19546056-2026-01-28-f23ada615c88))

## Sources

<a id="source-pubmed-observation-pmid-19546056-2026-01-28-f23ada615c88"></a>
- **Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study. · retained source version 1:2026-01-28:current:f23ada615c8852418e57fcd9370a05c6c42481ce21261cf8cbd95b4443e36e4c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19546056/) (`pubmed-observation-pmid-19546056-2026-01-28-f23ada615c88`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-19546056-pramlintide-v1.json SHA-256: 877e40b72bd004378e6728031db5d991f5f5507dd44ca07b6508fce005844230.